Worth Reading
What we are reading, and why.
Articles, guidance, and commentary from regulators, industry, and other experts that we think are worth your time. The subjects range as widely as our work does, from new regulations and modalities to process change, automation, and AI.
Worth Reading
11-06-2026
FDA Warning Letter highlights risks of using AI in drug manufacturing
An April 2026 warning letter for cGMP documents generated by AI agents without Quality Unit review: the failure that human-in-the-lead governance prevents.
11-05-2026
GxP Inspection-Ready AI Tools: Building Risk-Based QA Frameworks for AI/ML in GxP Operations
Six steps from intended use to change control and monitoring. "An AI system that cannot be governed should not be used for GxP purposes."
11-04-2026
EMA adopts reflection paper on AI/ML in drug development
How Europe frames AI across the whole medicinal product lifecycle, manufacturing and pharmacovigilance included: risk-based, with "high regulatory impact" and "high patient risk" aligned to the EU AI Act.
11-03-2026
Use of AI for GXP inspection responses: setting standards without stifling innovation
The MHRA Inspectorate on AI-drafted responses with invented references, and why every response needs experienced review and an accountable signature.
11-02-2026
FDA Warning Letter to ABS Corporation, 23 July 2026
Out-of-specification results averaged away, an in-process limit overwritten to fit the data, and batches released anyway. Specifications are not negotiable, and the evidence shows when they were.
08-24-2026
Looking at Innovation Under QMSR
How a device company can build a development system that absorbs change without losing discipline, now that FDA's QMSR expects risk management and regulatory planning across the whole product lifecycle.


